Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.06.

EBIT: As of FY2026 Q2, the actual value is USD -1.722 M.

Financial Performance for Three Months Ended June 30, 2026, vs. 2025

Research and Development (R&D) Expense

Research and Development (R&D) expense increased to $2.8 million in Q2 2026 from $1.8 million in Q2 2025. This rise was primarily due to a $0.9 million increase in non-cash stock-based compensation and a $0.1 million increase in consulting and professional fees.

General and Administrative (G&A) Expense

General and Administrative (G&A) expense increased to $7.4 million in Q2 2026 from $5.2 million in Q2 2025. This was mainly driven by a $1.4 million increase in non-cash stock-based compensation, a $0.3 million increase in other labor costs, and $0.4 million related to commercial launch preparation.

Total Operating Expenses

Total operating expenses rose to $10.140 million in Q2 2026 from $6.963 million in Q2 2025.

Loss from Operations

Loss from operations increased to - $10.140 million in Q2 2026 from - $6.963 million in Q2 2025.

Other Income (Expenses)

Interest income increased to $0.441 million in Q2 2026 from $0.155 million in Q2 2025. Interest expense was $0 in Q2 2026 compared to - $0.013 million in Q2 2025. Change in fair value of warrant liability increased significantly to $7.977 million in Q2 2026 from $0.374 million in Q2 2025. Total other income (expenses) rose to $8.418 million in Q2 2026 from $0.516 million in Q2 2025.

Net Loss

Net loss decreased to - $1.722 million in Q2 2026 from - $6.447 million in Q2 2025, primarily attributed to a decrease in the fair value of the Company’s warrant liability.

Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted

Net loss per share attributable to common stockholders, basic and diluted, was - $0.06 in Q2 2026, an improvement from - $0.52 in Q2 2025.

Unrealized Loss on Marketable Securities, Net

Unrealized loss on marketable securities, net, was - $0.029 million in Q2 2026, compared to $0 in Q2 2025.

Net Comprehensive Loss

Net comprehensive loss was - $1.751 million in Q2 2026, down from - $6.447 million in Q2 2025.

Balance Sheet Highlights (in thousands)

Cash and Cash Equivalents

Cash and cash equivalents totaled $44,185 as of June 30, 2026, up from $29,198 as of December 31, 2025.

Marketable Securities

Marketable securities increased to $17,240 as of June 30, 2026, from $12,071 as of December 31, 2025.

Total Current Assets

Total current assets stood at $71,320 as of June 30, 2026, compared to $48,961 as of December 31, 2025.

Total Assets

Total assets reached $72,029 as of June 30, 2026, up from $49,135 as of December 31, 2025.

Warrant Liability

Warrant liability decreased to $13,718 as of June 30, 2026, from $16,915 as of December 31, 2025.

Total Liabilities

Total liabilities were $18,759 as of June 30, 2026, slightly down from $18,938 as of December 31, 2025.

Total Stockholders’ Equity

Total stockholders’ equity increased to $53,270 as of June 30, 2026, from $30,197 as of December 31, 2025.

Operational Metrics and Outlook

As of June 30, 2026, Unicycive Therapeutics, Inc. reported unaudited cash, cash equivalents, and marketable securities totaling $61.4 million, which is expected to provide a financial runway into 2027. The company anticipates resubmitting the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) pending a successful inspection of its third-party manufacturing vendor, an inspection that the FDA has already assigned. Unicycive Therapeutics, Inc. is also advancing commercial readiness initiatives for OLC, including optimizing patient access and planning support through its UniSource™ reimbursement hub.